Valera Pharmaceuticals Inc

Valera Pharmaceuticals — Indevus Pharmaceuticals — Merger or Acquisition (December 2006)

26 slides from Valera Pharmaceuticals's merger presentation, Dec 12, 2006

  1. Slide 1: Acquisition of Valera Pharmaceuticals

    Exhibit 99.3 Acquisition of Valera Pharmaceuticals December 12, 2006

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. Such statements include, but are not limited to, the timing of completion of the tran

  3. Slide 3: Indevus 2006 – A Year of Milestone Achievement

    Indevus 2006 – A Year of Milestone Achievement • Acquired U.S. rights to DELATESTRYL® • Completed enrollment of NEBIDO® Phase III PK study • Announced positive results of pagoclone stuttering trial • Announced positive results of SANCTURA XR™ Phase III studies • Completed $35.0 million secondary off

  4. Slide 4: Strategic Rationale

    Strategic Rationale Acquisition creates an emerging leader in urology and men’s health • Perfect fit with the Indevus corporate strategy of building a world class urology and men’s health franchise • Upon closing, the combined Company will have 3 marketed products (one from Valera) and anticipates 5

  5. Slide 5: Indevus + Valera – Product Pipeline

    Indevus + Valera – Product Pipeline Building a Focused Portfolio of Products CORE THERAPEUTIC AREAS Phase I Phase II Phase III NDA Market SANCTURA® Overactive bladder VANTAS ® Prostate Cancer DELATESTRYL ® Hypogonadism VALSTAR ® Bladder Cancer Central Precocious SUPPRELIN® -LA Puberty SANCTURA XR ™

  6. Slide 6: Indevus + Valera – Product Pipeline

    Indevus + Valera – Product Pipeline Partnered & Partnerable Products OTHER THERAPEUTIC AREAS Preclinical Phase I Phase II Phase III Market Pagoclone Stuttering IP 751 Anti-inflammatory Disorders Naltrexone Implant Drug Addiction Hydron Implant Tech Other Uses Sarafem PMDD Licensed to Eli Lilly/Galen

  7. Slide 7: Transaction Overview

    Transaction Overview • Stock for Stock purchase of Valera Pharmaceuticals (VLRX) • $7.75 per share of Valera common stock with 10% collar Maximum exchange ratio: 1.1766 Minimum exchange ratio: 0.9626 • Deal Value ~ $120 Million + contingent payments • Contingent Payments in Indevus stock: $1.00/shar

  8. Slide 8: Indevus Product Portfolio: SANCTURA XR

    Indevus Product Portfolio SANCTURA XR™ - Overactive Bladder Current Profile of SANCTURA® Only quaternary ammonium on the market Low CNS side-effects No clinically relevant metabolic drug-drug interactions Excreted largely unchanged in the urine Rapid onset of action PLUS Once-a-day dosing Lower anti

  9. Slide 9: Indevus Product Portfolio: Co-Promotion Financial Terms with Esprit Pharma

    Indevus Product Portfolio Co-Promotion Financial Terms with Esprit Pharma Up Front and Approval Milestone $150M Phase III Initiation Milestone $ 10M NDA Submission $ 10M Future Milestones: Approval $35M Commercialization (2013) $20M Royalty Rates Guaranteed Minimum Royalties 15% $ 0 - $ 75M 7/1/05-6

  10. Slide 10: Indevus Product Portfolio: NEBIDO

    Indevus Product Portfolio NEBIDO® - Hypogonadism • Novel, long-acting preparation of testosterone undecanoate • First and ONLY 3-month injection • Approved in over 80 countries • Phase III pharmacokinetic study complete – Q2 2007 • Anticipated NDA submission – Summer 2007 • Highly differentiable fro

  11. Slide 11: Indevus Product Portfolio: Pagoclone

    Indevus Product Portfolio Pagoclone - Persistent Stuttering • Over 3 million patients in the U.S. with persistent stuttering • Novel, selective GABA-A receptor agonist • Complete toxicology, pharmacology and manufacturing packages for NDA with more than 1,000 patients studied in previous anxiety tri

  12. Slide 12: Indevus Product Portfolio: PRO 2000

    Indevus Product Portfolio PRO 2000 - Prevention of Sexual Transmission of HIV • Topical vaginal microbicide blocks pathogen entry into susceptible cells • Active against a wide range of HIV isolates, chlamydia, herpes and gonorrhea • Significant interest in female-controlled option • >$100M in desig

  13. Slide 13: Valera Product Portfolio: VANTAS

    Valera Product Portfolio VANTAS ® (histrelin implant) - Advanced Prostate Cancer • U.S. launch - November 2004 • Soft, flexible implant utilizing Hydron Implant Technology • 12-month implant to deliver histrelin (most potent LHRH agonist) for the treatment of advanced prostate cancer Limits need for

  14. Slide 14: VANTAS Co-Promotion Financial Terms with Indevus

    Valera Product Portfolio VANTAS ® Co-Promotion Financial Terms with Indevus • Separate agreement to co-promote VANTAS ® • Indevus sales force to initiate co-promotion activities in January 2007 Indevus ~ 85 reps Valera ~ 25 reps • 2-year term • Royalty rates: 13.5% of VANTAS ® sales up to a baseline

  15. Slide 15: Valera Product Portfolio: SUPPRELIN-LA

    Valera Product Portfolio SUPPRELIN®-LA - Central Precocious Puberty • 12-month specifically formulated implant to deliver histrelin for the treatment of central precocious puberty (CPP) • Provides consistent, reliable suppression for a 12- month period • FDA Granted Orphan Drug Status in November 20

  16. Slide 16: SUPPRELIN-LA – Central Precocious Puberty

    Valera Product Portfolio SUPPRELIN®-LA - Central Precocious Puberty • CPP is the early onset of puberty in young children • Incidence: 1 in every 5,000 – 10,000 children More common in female children Patient age: typically under 9 years; as young as 4 years or less Duration of therapy: 3 to 5 years

  17. Slide 17: SUPPRELIN-LA – Market Opportunity

    Valera Product Portfolio SUPPRELIN®-LA - Market Opportunity Offer parents a choice This Or 13 - 17 injections per year for 3 to 5 years SUPPRELIN®-LA Sample Responses From Surveyed Ped Endos • Implant conceptually attractive - easier on families; less traumatic for kids • Steady 1-year hormonal supp

  18. Slide 18: Valera Product Portfolio: VALSTAR

    Valera Product Portfolio VALSTAR ® (valrubicin) - Bladder Cancer • Anthracycline derivative of Doxorubicin solution for bladder instillation • Current approved usage 29,000 BCG refractory patients per year (AUA est.) • 15,000 – not candidates for bladder removal • Valstar ® is the only approved prod

  19. Slide 19: Valera Product Portfolio: Octreotide Implant

    Valera Product Portfolio Octreotide Implant - Acromegaly • 6 month octreotide (somatostatin analog) implant to treat acromegaly • Acromegaly: a chronic hormonal disorder Excessive growth hormone & abnormal physical features Higher incidence of diabetes & cardiovascular disease • Current therapy: San

  20. Slide 20: Octreotide Implant – Acromegaly

    Valera Product Portfolio Octreotide Implant - Acromegaly • Approximately 1,000 new acromegaly patients per year Treated by endocrinologists • Completed Phase I/II study demonstrating significant suppression of growth hormone and IGF-1 levels for 6 months • Commencing Phase II pharmacokinetic study i

  21. Slide 21: Valera Product Portfolio: Biodegradable Ureteral Stent

    Valera Product Portfolio Biodegradable Ureteral Stent • Presently, conventional non-biodegradable stents are inserted into the ureter to allow urine to drain when the flow of urine may be obstructed Approximately 1.2 million procedures per year for the removal of kidney stones in U.S. Estimated 800,

  22. Slide 22: Financial Highlights

    Financial Highlights Valera 14.9 million shares outstanding $19.9 million in LTM revenues $11.0 million in LTM Net Loss $18.9 million in Cash (9/30/06) No Debt Combined Company – pro forma $70.4 million in LTM revenues $95.0 million in Cash (9/30/06) Acquisition expected to be accretive within 2 yea

  23. Slide 23: Integration Plan

    Integration Plan • Expected Closing – on or around April 30, 2007 Subject to Indevus and Valera shareholder approval HSR clearance Other customary conditions of merger agreement • Indevus President/COO & Indevus EVP/Chief Business Officer to lead integration planning • Cross-functional integration t

  24. Slide 24: 2007 Milestones

    2007 Milestones Begin VANTAS ® co-promotion Pagoclone Phase III initiation SUPPRELIN®-LA approval and launch VALSTAR ® supplemental NDA submission NEBIDO® NDA submission SANCTURA XR™ approval and launch Octreotide Implant Phase III initiation Biodegradable Ureteral Stent 510k submission

  25. Slide 25: Additional Information and Where to Find It

    Additional Information and Where to Find It In connection with the merger between Indevus and Valera, Indevus intends to file with the SEC a registration statement on Form S-4, containing a joint proxy statement/prospectus and other relevant materials. The final joint proxy statement/prospectus will

  26. Slide 26: VALERA Pharmaceuticals

    VALERA Pharmaceuticals

Indevus Pharmaceuticals — Merger or Acquisition (December 2006) on 6ix